Physician profile
Jennifer Reeves
NPI 1720700529
$20,575.83
in general payments reported to CMS, 2019-2025
56 companies · $8,417 in 2025
The $8,417 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $247 · 2023: $3,317 · 2024: $8,595 · 2025: $8,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $4,071 · Consulting Fee: $2,475 · Education: $44.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,737.18 |
| Travel and Lodging | $4,071.35 |
| Consulting Fee | $2,475.00 |
| Education | $44.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $4,992.44 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Boston Scientific Corporation | $3,360.95 | 2023-2025 | Vercise, General - Dbs, General - Therapies |
| Abbvie INC. | $1,125.60 | 2023-2025 | |
| Lilly USA, LLC | $1,024.64 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $797.56 | 2022-2025 | Zilbrysq, Briviact, Rystiggo |
| Pfizer INC. | $763.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $651.28 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $600.72 | 2023-2025 | Rexulti, Nuedexta |
| Jazz Pharmaceuticals INC. | $558.28 | 2022-2025 | |
| Sk Life Science, INC. | $527.44 | 2022-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $494.07 | 2022-2025 | Ultomiris |
| Csl Behring | $486.03 | 2022-2025 | Hizentra |
| Lundbeck LLC | $479.55 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $435.46 | 2024-2025 | |
| Genentech USA, INC. | $422.28 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $315.85 | 2023-2025 | Gocovri, Gocovri |
| Acadia Pharmaceuticals INC | $272.74 | 2023-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $264.56 | 2025 | Symbravo, Sunosi |
| Biogen, INC. | $238.16 | 2023-2025 | Vumerity, Skyclarys, Spinraza |
| Harmony Biosciences LLC | $234.90 | 2023-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $218.04 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $207.25 | 2023-2025 | Hyqvia, Gammagard |
| Tg Therapeutics, INC. | $199.32 | 2025 | |
| Nevro Corp. | $189.38 | 2023 | Senza |
| Emd Serono, INC. | $157.09 | 2024-2025 | |
| Grifols USA, LLC | $129.67 | 2023-2024 | Gamunex-C |
| Idorsia Pharmaceuticals US INC | $127.61 | 2022-2023 | Quviviq |
| Tanabe Pharma America, INC. | $119.87 | 2023-2025 | Radicava |
| Impel Pharmaceuticals INC. | $107.07 | 2023 | Trudhesa |
| Acorda Therapeutics, INC | $98.82 | 2022-2023 | Inbrija |
| Merz Pharmaceuticals, LLC | $97.41 | 2025 | Xeomin, Inbrija, Ampyra |
| Catalyst Pharmaceuticals, INC. | $88.49 | 2024 | |
| Celgene Corporation | $84.24 | 2025 | Zeposia |
| Medtronic, INC. | $74.00 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Ge Healthcare | $70.27 | 2024 | |
| Octapharma USA, INC. | $62.28 | 2023-2025 | Panzyga |
| Ani Pharmaceuticals, INC. | $46.55 | 2024-2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $44.23 | 2025 | Ponvory |
| Janssen Biotech, INC. | $38.76 | 2025 | |
| Merck Sharp & Dohme LLC | $38.59 | 2023 | Belsomra |
| C2n Diagnostics, LLC | $37.84 | 2025 | Precivityad2 |
| Avadel Cns Pharmaceuticals, LLC | $32.43 | 2025 | Lumryz |
| Amneal Pharmaceuticals LLC | $30.23 | 2023-2024 | Rytary |
| Xeris Pharmaceuticals, INC. | $28.46 | 2023-2024 | Keveyis |
| Globus Medical, INC. | $24.75 | 2025 | Senza |
| Amgen INC. | $22.59 | 2023 | Aimovig |
| Genzyme Corporation | $20.75 | 2025 | |
| Cala Health, INC. | $19.26 | 2025 | Cala Kiq |
| Horizon Therapeutics Plc | $18.04 | 2023 | Uplizna |
| Scilex Pharmaceuticals INC. | $17.14 | 2023 | Ztlido |
| International Rehabilitative Sciences, INC | $14.82 | 2025 | Rs-4i Plus With Intersperse |
| Vertex Pharmaceuticals Incorporated | $14.50 | 2025 | |
| Neurocrine Biosciences, INC. | $13.95 | 2025 | |
| Azurity Pharmaceuticals, INC. | $13.76 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.70 | 2022 | |
| Life Molecular Imaging Ltd | $8.29 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.